Suprelorin
Active substance
ATC code
Species
Dogs, cats (male).
Indications
Male dogs:
For the induction of temporary infertility in healthy, intact, sexually mature male dogs.
Prepubertal female dogs:
For the induction of temporary infertility to delay the first oestrus and heat signs, and to prevent pregnancy at a young age in intact and healthy sexually immature female dogs. The implant should be administered between 12 and 16 weeks of age.
Male cats:
For the induction of temporary infertility and suppression of urine odour and of sexual behaviours such as libido, vocalisation, urine marking, and aggressiveness in intact male cats from 3 months of age.
Dose to be administered and administration route
Subcutaneous use.
The recommended dose is one implant per dog or cat, irrespective of the size of the dog or the cat (see also point 3.4).
Disinfection of the implantation site should be undertaken prior to implantation to avoid introduction of infection. If the hair is long, a small area should be clipped, if required.
The veterinary medicinal product should be implanted subcutaneously under the loose skin on the back between the lower neck and the lumbar area. Avoid injection of the implant into fat, as release of the active substance might be impaired in areas of low vascularisation.
1. Remove Luer Lock cap from the implanter.
2. Attach the actuator to the implanter using the Luer Lock connection.
3. Lift the loose skin between the shoulder blades. Insert the entire length of the needle subcutaneously.
4. Fully depress the actuator plunger and, at the same time, slowly withdraw the needle.
5. Press the skin at the insertion site as the needle is withdrawn, and maintain pressure for 30 seconds.
6. Examine the syringe and needle to ensure that the implant has not remained within the syringe or needle, and that the spacer is visible. It may be possible to palpate the implant in situ.
Repeat administration every 6 months to maintain efficacy in male dogs and every 1 year to maintain efficacy in male cats.
Do not use the veterinary medicinal product if the foil pouch is broken.
The implant is biocompatible and does not require removal. However, should it be necessary to end treatment, the implant or its fragments may be surgically removed by a veterinarian. Implants may be located using ultrasound.
Adverse reactions
Dogs (male and female):
Common (1 to 10 animals / 100 animals treated): | |
Rare (1 to 10 animals / 10,000 animals treated): | Hair change (Hair loss, Alopecia, Hair modification) Urinary incontinence Reduced testicle size Decreased activity, Weight gain |
Very rare (<1 animal / 10,000 animals treated, including isolated reports): | Ascending testicle3, Increased testicle size4, Testicular pain4 Increased sexual interest5, Aggression5 Epileptic seizures6 |
Undetermined frequency (Cannot be estimated from the available data): | Delayed growth plates closure7 |
3Through the inguinal ring
4Immediately following implantation, transitory, resolving without treatment
5Transient
6On average 40 days after implantation, median time to onset of signs was 14 days after implantation, on the same day of implantation at the earliest, and 36 weeks after implantation at the latest. Sexual hormones (testosterone and progesterone) modulate seizure susceptibility in humans and animals. 7In long-bones without clinical or pathological consequences
Cats:
Common (1 to 10 animals / 100 animals treated): | Increased appetite1, Weight gain1 Implant site reaction (Implant site redness2, Implant site pain2, Implant site warmth2, Implant site swelling3,4) |
Undetermined frequency (Cannot be estimated from the available data): | Increased sexual interest, Roaming5 Delayed growth plates closure6 |
1Up to 10 % during the period of effect
2On the day of implantation, transient
3Swelling < 5 mm, for up to 45 days
4Severe swelling (> 4 cm) lasting for more than 7 months reported in 1 out 18 cats in a laboratory study
5During the first weeks post implantation, transiently in mature male cats 6In long-bones without clinical or pathological consequences
Reporting adverse events is important. It allows continuous safety monitoring of a veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to either the marketing authorisation holder or its local representative or the national competent authority via the national reporting system. See the package leaflet for respective contact details.
